ReproCELL Incorporated (TYO:4978)
Japan · Delayed Price · Currency is JPY 119.00
-3.00 (-2.46%)
Jun 24, 2026, 1:03 PM JST
ReproCELL Revenue
In the fiscal year ending March 31, 2026, ReproCELL had annual revenue of 2.23B JPY, down -25.02%. ReproCELL had revenue of 624.00M in the quarter ending March 31, 2026, a decrease of -31.43%.
Revenue
2.23B
Revenue Growth
-25.02%
P/S Ratio
5.19
Revenue / Employee
22.56M
Employees
99
Market Cap
11.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.23B | -745.00M | -25.02% |
| Mar 31, 2025 | 2.98B | 552.00M | 22.75% |
| Mar 31, 2024 | 2.43B | -527.00M | -17.85% |
| Mar 31, 2023 | 2.95B | 719.00M | 32.18% |
| Mar 31, 2022 | 2.23B | 948.00M | 73.72% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RaQualia Pharma | 3.82B |
| StemCell Institute | 2.81B |
| Immuno-Biological Laboratories | 1.00B |
| OncoTherapy Science | 808.00M |
| Stella Pharma | 323.00M |
| Nano Holdings | 174.00M |
| CellSeed | 161.00M |
| Kubota Pharmaceutical Holdings | 17.76M |
ReproCELL News
- 4 months ago - ReproCELL Quarterly report: Q3 2026 - Filings
- 7 months ago - ReproCELL Quarterly report: Q2 2026 - Filings
- 11 months ago - ReproCELL Quarterly report: Q1 2026 - Filings